Final answer:
Baseline labs before starting tacrine should include liver function tests (LFTs) such as ALT, AST, ALP, and bilirubin levels, as tacrine can cause hepatotoxicity. Complete blood count and infection screening are also advisable. Regular monitoring is essential to optimize treatment and minimize health risks.
Step-by-step explanation:
Before starting tacrine, an acetylcholinesterase inhibitor used in the management of Alzheimer's disease, certain baseline labs should be taken to monitor its potential hepatotoxic effects. It is important to measure liver function tests (LFTs) including alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and bilirubin levels. Regular monitoring is crucial as tacrine can cause significant increases in liver enzymes. Moreover, complete blood count (CBC) and evaluations for signs of active or recent infection should also be considered due to the rare instance of immune-mediated reactions.
Patients should also be assessed for symptoms of jaundice, malaise, or anorexia which are indicative of liver dysfunction. It is essential for healthcare providers to ensure that patients understand the necessity for routine laboratory monitoring during tacrine therapy. This careful oversight assists in optimizing therapy while minimizing risks to patient health.